Potent small molecule CCR1 antagonists.

Kath, John C; Brissette, William H; Brown, Matthew F; Conklyn, Maryrose; DiRico, Amy P; Dorff, Peter; Gladue, Ronald P; Lillie, Brett M; Lira, Paul D; Mairs, Erin N; Martin, William H; McElroy, Eric B; McGlynn, Molly A; Paradis, Timothy J; Poss, Christopher S; Stock, Ingrid A; Tylaska, Laurie A; Zheng, Deye

Kath, John C; Brissette, William H; Brown, Matthew F; Conklyn, Maryrose; DiRico, Amy P; Dorff, Peter; Gladue, Ronald P; Lillie, Brett M; Lira, Paul D; Mairs, Erin N; Martin, William H; McElroy, Eric B; McGlynn, Molly A; Paradis, Timothy J; Poss, Christopher S; Stock, Ingrid A; Tylaska, Laurie A; Zheng, Deye.

Afiliação

Kath JC; Pfizer Global Research and Development, Eastern Point Road, Groton, CT 06340, USA. john_c_kath@groton.pfizer.com

Bioorg Med Chem Lett ; 14(9): 2169-73, 2004 May 03.

Article em En | MEDLINE | ID: mdl-15081002

ABSTRACT

ABSTRACT

The present manuscript details structure-activity relationship studies of lead structure 1, which led to the discovery of CCR1 antagonists >100-fold more potent than 1.

Assuntos

Receptores de Quimiocinas/antagonistas & inibidores; Linhagem Celular; Humanos; Receptores CCR1; Relação Estrutura-Atividade

Buscar no Google

Imprimir

XML

PubMed Links

Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Receptores de Quimiocinas Limite: Humans Idioma: En Revista: Bioorg Med Chem Lett Ano de publicação: 2004 Tipo de documento: Article

Buscar no Google

Imprimir

XML

PubMed Links